• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Siga lands $629m BARDA contract to stockpile smallpox treatment

September 11, 2018 By Sarah Faulkner

SIGA Technologies logoSiga Technologies (NSDQ:SIGA) said today that it signed a multi-year contract with the Biomedical Advanced Research & Development Authority to provide oral and intravenous versions of Siga’s Tpoxx smallpox treatment to the Strategic National Stockpile.

The contract, which is valued at up to $629 million, also includes funding for advanced development of the the drug’s IV formulation and post-marketing activities for Tpoxx’s oral formulation.

According to the contract, Siga and BARDA will work to maintain a stockpile of 1.7 million courses of the antiviral treatment at the Strategic National Stockpile.

The FDA approved Siga’s oral formulation of tecovirimat in July as a treatment for smallpox in the case of a potential outbreak.

The drug is designed to mitigate the impact of a bioterrorism attack involving smallpox, according to the New York-based company. Siga also reported this year that the FDA granted its request for a priority review voucher, giving the company the option for accelerated FDA review of a future product.

“This contract builds on the strong foundation of the Siga and BARDA partnership and we look forward to working closely with BARDA to ensure the current U.S. stockpile is adequately maintained,” CEO Phil Gomez said in prepared remarks. “The contract provides excellent value to the U.S. government for the mitigation of the risks of a smallpox outbreak, outlines a roadmap for sustaining the current stockpile, and adds the IV formulation of Tpoxx as an available alternative treatment option.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: sigatechnologies

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS